To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...

In reflecting on their journeys, multiple myeloma care partners share crucial insights they wish they’d known sooner.

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...

Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

Hip-hop and storytelling can enhance health communication, making messages resonate more authentically with underserved ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Heather Cooper Ortner leads the International Myeloma Foundation, focusing on advancing research, improving patient access, and enhancing support for myeloma care. The International Myeloma Foundation ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S ...

"If you're able to give blood, please God almighty, do it," Pat Still says. Radio personality Pat Still with Sacramento's ...